$VBIO Cashflow Statement | Understand Stock

$VBIO

$0.84 -$0.10 (10.64%) Close

$VBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Cash flows from operating activities
Net loss
Less: net loss from discontinued operations
Net loss from continuing operations
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation
Depreciation
Amortization of debt discount and debt issuance costs
Non-cash interest expense
Change in fair value of derivative liability
Issuance of warrants for services
Accounts receivable allowances
Amortization of right-of-use asset
Reserve for inventory obsolescence
Write-off offering costs related to unclosed financing arrangements
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Lease liabilities
Net cash used in operating activities - continuing operations
Net cash used in operating activities - discontinued operations
Net cash used in operating activities
Cash flows from investing activities
Issuance of note receivable
Acquisition of property and equipment
Acquisition of licensed technology
Net cash used in investing activities
Cash flows from financing activities
Proceeds from exercise of stock options
Issuance costs in connection with senior convertible note
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of common stock and warrants, net of issuance costs
Proceeds from issuance of preferred stock and warrants, net of issuance costs
Proceeds from warrant exercises
Offering costs in advance of sale of common stock
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Beginning of period
End of period
Less: cash and cash equivalents included in discontinued operations
Cash and cash equivalents included in continuing operations
Cash paid for income tax
Issuance of common stock warrant
Deferred offering costs charged to additional paid-in-capital
Write-off of ROU asset and lease liability

Supplemental disclosure on non-cash financing activities
Convertible note issued in exchange for purchase of Scorpius assets and goodwill
Warrants issued to placement agents as non-cash offering fees
Issuance of equity
Issuance of Stock in Exchange for License
Issuance of Stock for Equity Line of Credit
Issuance of Warrants for Discount Related Party Convertible Note Payable
Non-cash recognition of embedded derivative liability on issuance of convertible notes
Dividends declared
Deemed dividends
Write-off of ROU asset and lease liability

Comments